Abstract
Objective: The objective of this study was to assess the relationship between serum procalcitonin (PCT) and acute kidney injury (AKI) induced by bacterial septic shock. Methods: A retrospective study was designed which included patients who were admitted to the ICU from January 2015 to October 2018. Multiple logistic regression and receiver operating characteristic (ROC) as well as smooth curve fitting analysis were used to assess the relationship between the PCT level and AKI. Results: Of the 1,631 patients screened, 157 patients were included in the primary analysis in which 84 (53.5%) patients were with AKI. Multiple logistic regression results showed that PCT (odds ratio [OR] = 1.017, 95% confidence interval [CI] 1.009–1.025, p < 0.001) was associated with AKI induced by septic shock. The ROC analysis showed that the cutoff point for PCT to predict AKI development was 14 ng/mL, with a sensitivity of 63% and specificity 67%. Specifically, in multivariate piecewise linear regression, the occurrence of AKI decreased with the elevation of PCT when PCT was between 25 ng/mL and 120 ng/mL (OR 0.963, 95% CI 0.929–0.999; p = 0.042). The AKI increased with the elevation of PCT when PCT was either <25 ng/mL (OR 1.077, 95% CI 1.022–1.136; p = 0.006) or >120 ng/mL (OR 1.042, 95% CI 1.009–1.076; p = 0.013). Moreover, the PCT level was significantly higher in the AKI group only in female patients aged ≤75 years (p = 0.001). Conclusions: Our data revealed a nonlinear relationship between PCT and AKI in septic shock patients, and PCT could be used as a potential biomarker of AKI in female patients younger than 75 years with bacterial septic shock.
Journal Section:
Research Article
References
1.
Singer
M
, Deutschman
CS
, Seymour
CW
, Shankar-Hari
M
, Annane
D
, Bauer
M
, . The third international consensus definitions for sepsis and septic shock (Sepsis-3)
. JAMA
. 2016
;315
(8
):801
–10
.2.
Shankar-Hari
M
, Phillips
GS
, Levy
ML
, Seymour
CW
, Liu
VX
, Deutschman
CS
, . Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)
. JAMA
. 2016
;315
(8
):775
–87
.3.
Seymour
CW
, Liu
VX
, Iwashyna
TJ
, Brunkhorst
FM
, Rea
TD
, Scherag
A
, . Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)
. JAMA
. 2016
;315
(8
):762
–74
.4.
Angus
DC
, van der Poll
T
. Severe sepsis and septic shock
. N Engl J Med
. 2013
;369
(21
):2063
–51
.5.
Cecconi
M
, Evans
L
, Levy
M
, Rhodes
A
. Sepsis and septic shock
. Lancet
. 2018
;392
(10141
):75
–87
.6.
Fleischmann
C
, Scherag
A
, Adhikari
NK
, Hartog
CS
, Tsaganos
T
, Schlattmann
P
, . Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations
. Am J Respir Crit Care Med
. 2016
;193
(3
):259
–72
.7.
Bagshaw
SM
, Uchino
S
, Bellomo
R
, Morimatsu
H
, Morgera
S
, Schetz
M
, . Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes
. Clin J Am Soc Nephrol
. 2007
;2
(3
):431
–9
.8.
Bagshaw
SM
, George
C
, Bellomo
R
; ANZICS Database Management Committee
. Early acute kidney injury and sepsis: a multicentre evaluation
. Crit Care
. 2008
;12
(2
):R47
.9.
Karzai
W
, Oberhoffer
M
, Meier-Hellmann
A
, Reinhart
K
. Procalcitonin: a new indicator of the systemic response to severe infections
. Infection
. 1997
;25
(6
):329
–34
.10.
Maruna
P
, Nedelníková
K
, Gürlich
R
. Physiology and genetics of procalcitonin
. Physiol Res
. 2000
;49
(Suppl 1
):S57
–61
.11.
Snider
RH
Jr, Nylen
ES
, Becker
KL
. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization
. J Investig Med
. 1997
;45
(9
):552
–60
.12.
Wacker
C
, Prkno
A
, Brunkhorst
FM
, Schlattmann
P
. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis
. Lancet Infect Dis
. 2013
;13
(5
):426
–35
.13.
Hatzistilianou
M
. Diagnostic and prognostic role of procalcitonin in infections
. ScientificWorldJournal
. 2010
;10
:1941
–6
.14.
Wirz
Y
, Meier
MA
, Bouadma
L
, Luyt
CE
, Wolff
M
, Chastre
J
, . Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials
. Crit Care
. 2018
;22
(1
):191
.15.
Huang
HL
, Nie
X
, Cai
B
, Tang
JT
, He
Y
, Miao
Q
, . Procalcitonin levels predict acute kidney injury and prognosis in acute pancreatitis: a prospective study
. PLoS One
. 2013
;8
(12
):e82250
.16.
Kurtul
A
, Murat
SN
, Yarlioglues
M
, Duran
M
, Ocek
AH
, Celik
IE
, . Procalcitonin as an early predictor of contrast-induced acute kidney injury in patients with acute coronary syndromes who underwent percutaneous coronary intervention
. Angiology
. 2015
;66
(10
):957
–63
.17.
Shiao
CC
, Chueh
YF
, Yang
L
. Using procalcitonin to predict acute kidney injury in septic patients: caveat emptor
. J Formos Med Assoc
. 2019
;118
(2
):542
–4
.18.
Stevens
PE
, Levin
A
; Kidney disease: improving global outcomes chronic kidney disease guideline development work group members
. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline
. Ann Intern Med
. 2013
;158
(11
):825
–30
.19.
Wu
M
, Luan
YY
, Lu
JF
, Li
H
, Zhan
HC
, Chen
YH
, . Platelet count as a new biomarker for acute kidney injury induced by hemorrhagic shock
. Platelets
. 2020
;31
(1
):94
–102
.20.
Anon
JM
, Gomez-Tello
V
, Gonzalez-Higueras
E
, Córcoles
V
, Quintana
M
, García de Lorenzo
A
, . Prognosis of elderly patients subjected to mechanical ventilation in the ICU
. Med Intensiva
. 2013
;37
(3
):149
–55
.21.
Chun
K
, Chung
W
, Kim
AJ
, Kim
H
, Ro
H
, Chang
JH
, . Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients
. Sci Rep
. 2019
;9
(1
):4777
.22.
Wang
M
, Zhang
Q
, Zhao
X
, Dong
G
, Li
C
. Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: an observational study
. Crit Care
. 2014
;18
(6
):634
.23.
Zheng
CF
, Liu
WY
, Zeng
FF
, Zheng
MH
, Shi
HY
, Zhou
Y
, . Prognostic value of platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury
. Crit Care
. 2017
;21
(1
):238
.24.
Hotchkiss
RS
, Monneret
G
, Payen
D
. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
. Nat Rev Immunol
. 2013
;13
(12
):862
–74
.25.
Delano
MJ
, Ward
PA
. Sepsis-induced immune dysfunction: can immune therapies reduce mortality
. J Clin Invest
. 2016
;126
(1
):23
–31
.26.
Delano
MJ
, Ward
PA
. The immune system’s role in sepsis progression, resolution, and long-term outcome
. Immunol Rev
. 2016
;274
(1
):330
–53
.27.
Ma
S
, Evans
RG
, Iguchi
N
, Tare
M
, Parkington
HC
, Bellomo
R
, . Sepsis-induced acute kidney injury: a disease of the microcirculation
. Microcirculation
. 2019
;26
(2
):e12483
.28.
Post
EH
, Kellum
JA
, Bellomo
R
, Vincent
JL
. Renal perfusion in sepsis: from macro- to microcirculation
. Kidney Int
. 2017
;91
(1
):45
–60
.29.
Emlet
DR
, Shaw
AD
, Kellum
JA
. Sepsis-associated AKI: epithelial cell dysfunction
. Semin Nephrol
. 2015
;35
(1
):85
–95
.30.
Bellomo
R
, Kellum
JA
, Ronco
C
, Wald
R
, Martensson
J
, Maiden
M
, . Acute kidney injury in sepsis
. Intensive Care Med
. 2017
;43
(6
):816
–28
.31.
Sridharan
P
, Chamberlain
RS
. The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills
. Surg Infect
. 2013
;14
(6
):489
–511
.32.
Nie
X
, Wu
B
, He
Y
, Huang
X
, Dai
Z
, Miao
Q
, . Serum procalcitonin predicts development of acute kidney injury in patients with suspected infection
. Clin Chem Lab Med
. 2013
;51
(8
):1655
–61
.33.
Itenov
TS
, Jensen
JU
, Ostrowski
SR
, Johansson
PI
, Thormar
KM
, Lundgren
JD
, . Endothelial damage signals refractory acute kidney injury in critically Ill patients
. Shock
. 2017
;47
(6
):696
–701
.34.
Araujo
M
, Doi
SQ
, Palant
CE
, Nylen
ES
, Becker
KL
. Procalcitonin induced cytotoxicity and apoptosis in mesangial cells: implications for septic renal injury
. Inflamm Res
. 2013
;62
(10
):887
–94
.35.
Wiedermann
FJ
, Kaneider
N
, Egger
P
, Tiefenthaler
W
, Wiedermann
CJ
, Lindner
KH
, . Migration of human monocytes in response to procalcitonin
. Crit Care Med
. 2002
;30
(5
):1112
–7
.36.
Zheng
W
, Liang
X
, Shui
L
, Ye
B
, Lou
G
, Liu
Y
, . Serum procalcitonin correlates with renal function in hepatitis B virus-related acute-on-chronic liver failure
. Cell Physiol Biochem
. 2018
;50
(5
):1794
–803
.37.
Steinbach
G
, Bölke
E
, Grünert
A
, Störck
M
, Orth
K
. Procalcitonin in patients with acute and chronic renal insufficiency
. Wien Klin Wochenschr
. 2004
;116
(24
):849
–53
.38.
Nakamura
Y
, Murai
A
, Mizunuma
M
, Ohta
D
, Kawano
Y
, Matsumoto
N
, . Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or without acute kidney injury
. J Infect Chemother
. 2015
;21
(4
):257
–63
.39.
Jeeha
R
, Skinner
DL
, De Vasconcellos
K
, Magula
NP
. Serum procalcitonin levels predict acute kidney injury in critically ill patients
. Nephrology
. 2018
;23
(12
):1090
–5
.40.
Neugarten
J
, Golestaneh
L
, Kolhe
NV
. Sex differences in acute kidney injury requiring dialysis
. BMC Nephrol
. 2018
;19
(1
):131
.41.
Neugarten
J
, Golestaneh
L
. Female sex reduces the risk of hospital-associated acute kidney injury: a meta-analysis
. BMC Nephrol
. 2018
;19
(1
):314
.42.
Kane-Gill
SL
, Sileanu
FE
, Murugan
R
, Trietley
GS
, Handler
SM
, Kellum
JA
. Risk factors for acute kidney injury in older adults with critical illness: a retrospective cohort study
. Am J Kidney Dis
. 2015
;65
(6
):860
–9
.43.
Nie
S
, Feng
Z
, Tang
L
, Wang
X
, He
Y
, Fang
J
, . Risk factor analysis for AKI including laboratory indicators: a nationwide multicenter study of hospitalized patients
. Kidney Blood Press Res
. 2017
;42
(5
):761
–73
.© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
